Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 2
1997 1
1998 1
1999 1
2007 1
2009 2
2010 1
2011 1
2012 2
2013 2
2014 4
2015 2
2016 1
2017 1
2018 2
2019 1
2020 1
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

26 results
Results by year
Filters applied: . Clear all
Page 1
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates.
Purcell JW, Tanlimco SG, Hickson J, Fox M, Sho M, Durkin L, Uziel T, Powers R, Foster K, McGonigal T, Kumar S, Samayoa J, Zhang D, Palma JP, Mishra S, Hollenbaugh D, Gish K, Morgan-Lappe SE, Hsi ED, Chao DT. Purcell JW, et al. Among authors: chao dt. Cancer Res. 2018 Jul 15;78(14):4059-4072. doi: 10.1158/0008-5472.CAN-18-0327. Epub 2018 May 15. Cancer Res. 2018. PMID: 29764866 Free article.
BCL-2 family: regulators of cell death.
Chao DT, Korsmeyer SJ. Chao DT, et al. Annu Rev Immunol. 1998;16:395-419. doi: 10.1146/annurev.immunol.16.1.395. Annu Rev Immunol. 1998. PMID: 9597135 Review.
VISTA is an activating receptor in human monocytes.
Rogers BM, Smith L, Dezso Z, Shi X, DiGiammarino E, Nguyen D, Sethuraman S, Zheng P, Choi D, Zhang D, Nguyen A, McGuire K, Liu W, Chung N, Chao DT, Ye S, Starbeck-Miller GR. Rogers BM, et al. Among authors: chao dt. J Exp Med. 2021 Aug 2;218(8):e20201601. doi: 10.1084/jem.20201601. Epub 2021 Jun 9. J Exp Med. 2021. PMID: 34106206 Free PMC article.
A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity.
Ye S, Cohen D, Belmar NA, Choi D, Tan SS, Sho M, Akamatsu Y, Kim H, Iyer R, Cabel J, Lake M, Song D, Harlan J, Zhang C, Fang Y, Wahl AF, Culp P, Hollenbaugh D, Chao DT. Ye S, et al. Among authors: chao dt. Cancer Immunol Res. 2019 Nov;7(11):1864-1875. doi: 10.1158/2326-6066.CIR-18-0805. Epub 2019 Aug 28. Cancer Immunol Res. 2019. PMID: 31462409 Free article.
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
Luke JJ, Barlesi F, Chung K, Tolcher AW, Kelly K, Hollebecque A, Le Tourneau C, Subbiah V, Tsai F, Kao S, Cassier PA, Khasraw M, Kindler HL, Fang H, Fan F, Allaire K, Patel M, Ye S, Chao DT, Henner WR, Hayflick JS, McDevitt MA, Fong L. Luke JJ, et al. Among authors: chao dt. J Immunother Cancer. 2021 Feb;9(2):e002015. doi: 10.1136/jitc-2020-002015. J Immunother Cancer. 2021. PMID: 33608377 Free PMC article. Clinical Trial.
Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity.
Ho SK, Xu Z, Thakur A, Fox M, Tan SS, DiGiammarino E, Zhou L, Sho M, Cairns B, Zhao V, Xiong M, Samayoa J, Forsyth CM, Powers DB, Chao DT, Hollenbaugh D, Alvarez HM, Akamatsu Y. Ho SK, et al. Among authors: chao dt. Mol Cancer Ther. 2020 Apr;19(4):1040-1051. doi: 10.1158/1535-7163.MCT-19-0608. Epub 2020 Jan 23. Mol Cancer Ther. 2020. PMID: 31974274 Free article.
26 results